X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/bergenbio-announces-new-preclinical-data-indicating-broadened-potential-for-bemcentinib-to-treat-severe-respiratory-infections-302055930.html
https://www.prnewswire.com/news-releases/additional-data-on-bergenbios-selective-axl-inhibitor-bemcentinib-to-be-presented-at-the-2023-esmo-meeting-301957048.html
https://www.prnewswire.com/news-releases/bergenbio-announces-clinical-data-presentations-highlighting-the-activity-of-its-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-301906548.html
https://www.prnewswire.com/news-releases/bergenbio-announces-first-patient-dosed-in-phase-1b2a-trial-evaluating-bemcentinib-in-1st-line-non-small-cell-lung-cancer-with-stk11-mutations-301767796.html
https://www.clinicaltrialsarena.com/news/bergenbio-covid-treatment-study/
https://www.prnewswire.com/news-releases/bergenbio-and-oslo-university-hospital-announce-the-axl-inhibitor-bemcentinib-will-be-studied-in-the-eu-funded-eu-solidact-trial-in-hospitalised-covid-19-patients-301469371.html
https://www.prnewswire.com/news-releases/bergenbio-receives-fda-fast-track-designation-for-bemcentinib-in-stk11-mutated-advancedmetastatic-non-small-lung-cancer-nsclc-301419799.html
https://www.prnewswire.com/news-releases/bergenbio-receives-fda-fast-track-designation-for-bemcentinib--anti-pd-l1-combination-in-nsclc-301307422.html
https://www.prnewswire.co.uk/news-releases/bergenbio-to-present-top-line-translational-phase-ii-data-with-bemcentinib-in-combination-with-keytruda-r-in-nsclc-patients-at-next-gen-immuno-oncology-congress-892201104.html
https://www.theguardian.com/world/2020/jun/01/uk-hospitals-trial-five-new-drugs-search-coronavirus-treatment
http://www.pharmatimes.com/news/first_patient_dosed_in_bemcentinib_covid-19_trial_1341390
https://www.prnewswire.com/news-releases/bergenbio-confirms-first-covid-19-patient-dosed-with-bemcentinib-in-accord-trial-301068980.html
https://www.prnewswire.com/news-releases/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-301048867.html
https://www.prnewswire.co.uk/news-releases/bergenbio-s-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-849232914.html
https://www.prnewswire.com/news-releases/bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-nsclc-patients-progressing-on-immune-checkpoint-inhibitors-300987587.html
https://www.prnewswire.com/news-releases/bergenbio-presents-preliminary-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-in-elderly-aml-patients-at-ash-2019-300971109.html
http://www.pharmatimes.com/news/lynparza_shows_benefits_in_prostate_cancer_1318664
https://www.moneycontrol.com/news/business/companies/piramal-pharma-solutions-partners-with-norway-based-bergenbio-to-develop-blood-cancer-drug-4696561.html
http://www.pharmatimes.com/news/bemcentinib,_keytruda_combo_hits_endpoints_in_mid-stage_nsclc_trial_1315934
https://www.prnewswire.com/news-releases/bergenbio-to-present-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-trial-in-elderly-aml-patients-at-ash-2019-300953783.html
https://www.prnewswire.com/news-releases/bergenbio-receives-fda-approval-of-fast-track-designation-for-bemcentinib-300942973.html
https://www.fiercebiotech.com/biotech/bergenbio-posts-updated-data-trial-elderly-aml-patients
https://endpts.com/newsmakers-at-eha19-regeneron-arqule-track-progress-on-response-rates/
https://www.prnewswire.com/news-releases/bergenbio-presents-new-preliminary-clinical-and-biomarker-data-showing-durable-response--median-survival-rates-in-phase-ii-trial-with-bemcentinib-and-keytruda-in-pts-with-advanced-nsclc-at-asco-2019-300860276.html
https://www.biospectrumindia.com/news/43/15256/piramal-pharma-collaborates-with-bergenbio.html
http://www.prnewswire.co.uk/news-releases/bergenbio-to-present-late-breaking-abstract-on-phase-ii-trial-of-bemcentinib-in-combination-with-699375131.html
https://www.prnewswire.com/news-releases/bergenbio-enters-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc-300725087.html
https://www.prnewswire.com/news-releases/bergenbio-to-present-interim-clinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-in-aml-and-mds-at-eha-300650898.html
Market Place
Share 
